FI.CS.PRKNDex2/Dex5-7.F@40

The cell line is not validated yet.

General

Cell Line

hPSCreg name FINi006-A
Cite as:
FINi006-A (RRID:CVCL_D6I6)
Alternative name(s)
FI.CS.PRKNDex2/Dex5-7.F@40
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 24th July 2025
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator The Florey Institute of Neuroscience and Mental Health (FIN)
Owner The Florey Institute of Neuroscience and Mental Health (FIN)
Distributors
Derivation country Australia

External Databases

Cellosaurus CVCL_D6I6
Wikidata Q127380858

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 40-44

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
diagnosed at 21
Synonyms
  • Parkinson Disease
  • Parkinson's disease
  • Parkinson's Disease
Disease associated phenotypes
  • lack of PRKN protein
  • lack of mytofusin ubiquitination

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
23, XX

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
* Does consent expressly prevent the derivation of pluripotent stem cells? No
* Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? No
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? South Eastern Sydney Area Health Services
Approval number HREC Approval No:03/193
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? South Eastern Sydney Area Health Services
Approval number HREC Approval No:03/193
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: South Eastern Sydney area health Services and clinicians/researches who consented patient and initiated the study
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Any skin fibroblast that is part of some dermis.
Age of donor (at collection) 40-44
Passage number reprogrammed 5

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Average size, highest roundness and typical primed hiPSC morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Mechanically
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ Plus
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
SOX2
Yes
KLF4
Yes
Differentiation Potency
Definitive Endoderm
Ont Id: UBERON_0005439
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
TBXT
Yes
TBX6
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
OTX2
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
normal XX female
Passage number: 12

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
WGS
https://zenodo.org/records/13332144
WGS / analysis performed at Garvan Institute / University of Sydney